deoxycytidine and Biliary Tract Neoplasms

deoxycytidine has been researched along with Biliary Tract Neoplasms in 350 studies

Research

Studies (350)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.29)	18.2507
2000's	73 (20.86)	29.6817
2010's	204 (58.29)	24.3611
2020's	72 (20.57)	2.80

Authors

Authors	Studies
Aoki, T; Iso, Y; Kubota, K; Matsumoto, T; Mori, S; Park, KH; Sakuraoka, Y; Shimizu, T; Shiraki, T; Yamaguchi, T	1
Akouz, FK; Barbier, E; Bourgeois, V; Coriat, R; Dahan, L; Desrame, J; Edeline, J; Ghiringhelli, F; Lecomte, T; Louafi, S; Ly, VL; Malka, D; Manfredi, S; Michel, P; Molin, Y; Neuzillet, C; Perrier, H; Phelip, JM; Soularue, E; Terrebonne, E	1
Benatti, S; Brandi, G; Carotenuto, P; De Lorenzo, S; Dominici, M; Francesco, C; Frega, G; Gelsomino, F; Luppi, G; Melisi, D; Merz, V; Messina, C; Palloni, A; Pettorelli, E; Ricci, AD; Rizzo, A; Salati, M; Spallanzani, A	1
Komatsu, Y; Saito, Y; Sakamoto, T; Sugawara, M; Takekuma, Y; Uchiyama, K	1
Brandi, G; Ricci, AD; Rizzo, A	1
Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Mitsufuji, S; Mori, M; Noda, T; Tomimaru, Y; Ueno, G; Yamada, D	2
Hwang, JH; Jung, JH; Jung, K; Kim, J; Lee, JC; Park, J	1
Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Iwai, T; Kamata, K; Kataoka, T; Kato, N; Kawamoto, Y; Kojima, Y; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nishina, T; Okamura, K; Okano, N; Okusaka, T; Oono, T; Sekimoto, M; Shimizu, K; Shimizu, S; Shioji, K; Shirakawa, H; Sudo, K; Tobimatsu, K; Todaka, A; Ueno, M; Yamada, I; Yamaguchi, H; Yamashita, T	1
Aglietta, M; Aldrighetti, L; Aprile, G; Brandi, G; Burgio, V; Casadei-Gardini, A; Cascinu, S; Cucchetti, A; Faloppi, L; Fenocchio, E; Filippi, R; Fornaro, L; Frega, G; Galizia, E; Lai, E; Leone, F; Lonardi, S; Masi, G; Montagnani, F; Palloni, A; Pella, N; Pellino, A; Ratti, F; Rimini, M; Salani, F; Santini, D; Satolli, MA; Scartozzi, M; Silvestris, N; Sperti, E; Vivaldi, C	1
Ambo, Y; Ando, M; Benabdelghani, M; Bertaut, A; Ebata, T; Edeline, J; Hammel, P; Hirano, S; Joly, JP; Kaneoka, Y; Konishi, M; Louvet, C; Malka, D; Monard, L; Nagino, M; Ohtsuka, M; Phelip, JM; Uesaka, K; Watelet, J; Yamamoto, M	1
Neuzillet, C	1
Bhosale, P; Danner De Armas, A; Javle, M; Lee, S; Makawita, S; Pant, S; Raghav, K; Reddy, K; Shalaby, A; Shroff, RT; Wolff, RA; Xiao, L	1
Hindson, J	1
Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y	1
Cao, G; Chen, L; Dong, X; Liu, C; Lu, W; Song, T; Zhang, Q; Zhang, W; Zhang, Z	1
Bai, LY; Chao, Y; Chen, LT; Chen, MH; Chen, SC; Chen, SJ; Chiang, NJ; Hsiao, CF; Huang, CJ; Huang, CY; Huang, YH; Hung, YP; Lee, IC; Lee, PC; Shan, YS; Su, YY; Tan, KT; Yeh, CN	1
Chen, E; DeLuca, S; Dhani, N; Doherty, MK; Hedley, D; Jang, R; Knox, JJ; McNamara, MG; O'Kane, GM; Pedutem, T; Sim, HW; Tam, VC; Tang, P; Wang, L	1
Beg, MS; Deming, DA; Griffith, KA; Mahalingam, D; Sahai, V; Shaib, WL; Zalupski, MM; Zhen, DB	1
Funahara, H; Hiraki, K; Kikkawa, A; Matsumoto, S; Nakai, M	1
Assenat, E; Boleslawski, E; Camus, M; Delaye, M; Edeline, J; Henriques, J; Herrero, A; Lièvre, A; Malka, D; Neuzillet, C; Turpin, A; Vernerey, D	1
Baba, H; Eguchi, H; Hatano, E; Ioka, T; Kamachi, H; Kanai, M; Kobayashi, S; Nagano, H; Nakagami, Y; Sakai, D; Shindo, Y; Takahashi, M; Takayama, T; Ueno, M; Wada, H; Yoshimura, K	1
Chang, HM; Jeong, JH; Kim, D; Kim, HD; Kim, KP; Kim, M; Kim, SY; Lee, DS; Lee, S; Oh, CR; Ryoo, BY; Ryu, YM; Yoo, C	1
Long, J; Sang, X; Wang, S; Wang, Y; Xue, J; Yang, X; Zhang, L; Zhang, N; Zhao, H; Zhu, C	1
Aoyama, S; Hata, T; Hiraki, M; Ikeshima, R; Katsura, Y; Katsuyama, S; Kihara, Y; Kinoshita, M; Masuzawa, T; Muneta, M; Murata, K; Ohmura, Y; Shinke, G; Sugimura, K; Takeda, Y	1
Chen, DS; Chen, XY; Cheng, Z; Deng, WL; Dong, YL; Guo, LP; Han, Q; Lou, C; Qi, C; Shang, PP; Song, YJ; Tao, CJ; Wei, W; Xu, HM; Yang, G; Yuan, ZG; Zeng, TM	1
Kashiwa, M; Matsushita, R	1
Achreja, A; Animasahun, O; Chinnaiyan, AM; Choppara, S; Crysler, O; Dippman, D; Enzler, T; Griffith, KA; Gunchick, V; Hsiehchen, D; Kumar-Sinha, C; Mohan, A; Nagrath, D; Nenwani, M; Sahai, V; Wuchu, F; Zalupski, MM; Zhen, DB	1
Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A	1
Daiku, K; Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Miyashiro, I; Morishima, T; Mukai, K; Nakabori, T; Ohkawa, K; Seiki, Y; Takada, R; Uehara, H; Urabe, M; Watsuji, K; Yamai, T	1
Gou, H; Huang, Q; Li, X; Tan, S; Yang, Y; Zhang, S; Zhou, N	1
Avallone, A; Bouattour, M; Burris, H; Chen, JS; Chen, LT; Cohen, G; Cundom, J; He, AR; Ikeda, M; Kim, JW; Kitano, M; Kurland, JF; Lee, CK; Lee, MA; Makowsky, M; McNamara, MG; Oh, DY; Okusaka, T; Qin, S; Rokutanda, N; Suksombooncharoen, T; Takahashi, H; Tan, B; Tanasanvimon, S; Valle, JW; Vogel, A; Wang, J; Zaucha, R; Żotkiewicz, M	1
Dadzie, R; Johal, S; Paskow, M; Peirce, V; Prince, S; Qin, L; Rapoport, M	1
Fung, S; Syed, YY	1
Asagi, A; Gotoh, K; Ikeda, M; Imaoka, H; Mizuno, N; Morizane, C; Nakamura, K; Nomura, S; Okano, N; Okusaka, T; Ozaka, M; Sano, K; Satoi, S; Shimizu, S; Shirakawa, H; Sugimori, K; Sugimoto, R; Ueno, M; Yamaguchi, H; Yamazaki, K	1
Ojima, H; Okusaka, T; Sakamoto, Y; Yamagishi, S	1
Aglietta, M; Aimar, G; Fenocchio, E; Filippi, R; Leone, F; Lombardi, P; Milanesio, M; Quarà, V	1
Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S	1
Furukawa, K; Kagawa, S; Kuboki, S; Mishima, T; Miyazaki, M; Nakadai, E; Ohtsuka, M; Sakai, N; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H	1
Bridgewater, J	1
Furukawa, K; Kuboki, S; Miyazaki, M; Ohtsuka, M; Takayashiki, T; Yoshitomi, H	1
Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Goto, K; Gotoh, K; Hayashi, K; Iwagami, Y; Kinoshita, M; Kobayashi, S; Kubo, M; Maekawa, K; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Urakawa, S; Wada, H; Yamada, D	1
Alvaro, D; Begum, R; Boulter, L; Braconi, C; Cardinale, V; Carotenuto, P; Carpino, G; Cascione, L; Cillo, U; Clarke, P; Costantini, D; Cunningham, D; Fassan, M; Forbes, SJ; Ghidini, M; Guest, RV; Guzzardo, V; Hahne, JC; Hedayat, S; Kirkin, V; Lampis, A; Michalarea, V; Rimassa, L; Roncalli, M; Said-Huntingford, I; Salati, M; Santoro, A; Scarpa, A; Smyth, E; Te Poele, R; Trevisani, F; Valeri, N; Ventura, S; Vicentini, C; Vlachogiannis, G; Workman, P	1
Akara-Amornthum, P; Choksi, S; Jitkaew, S; Lomphithak, T; Tohtong, R	1
Belkouz, A; de Vos-Geelen, J; Eskens, FALM; Klümpen, HJ; Mathôt, RAA; Punt, CJA; van Gulik, TM; van Oijen, MGH; Wilmink, JW	1
Edeline, J	1
Buyuksimsek, M; Kidi, MM; Mirili, C; Ogul, A; Paydas, S	1
Sinn, M; Stein, A; Wege, H	1
Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D	1
Chang, JW; Chen, JS; Chou, WC; Hsieh, CH; Lin, CY; Wu, CE; Yeh, CN	1
Abdelrahman, A; Arora, M; Barrett, MT; Bogenberger, JM; Borad, MJ; Braggio, E; Chen, X; Egan, JB; Kasimsetty, A; Kosiorek, HE; Leiting, JL; Lenkiewicz, E; Malasi, S; Nagalo, BM; Salomao, MA; Truty, MJ; Uson, PLS; Zhou, Y	1
Borbath, I; Delaunoit, T; Demols, A; Goemine, JC; Holbrechts, S; Houbiers, G; Laurent, S; Marechal, R; Paesmans, M; Peeters, M; Van den Eynde, M; Van Laethem, JL	1
Buyuksimsek, M; Kidi, MM; Ogul, A	1
Bartoli, L; Messori, A; Trippoli, S	1
Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW	1
Akhoundova Sanoyan, D; Lamarca, A; McNamara, MG; Valle, JW	1
Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K	1
Lamarca, A; Valle, JW	1
Ichikura, D; Ichimura, T; Kawashima, W; Minemura, A; Murakami, K; Nawata, S; Sasaki, T; Usuda, M	1
Jin, J; Zhang, Y; Zheng, T; Zhou, L	1
Fu, J; McGrath, NA; Monge Bonilla, C; Xie, C	1
Andersen, JB; Boisen, MK; Dang, H; Dehlendorff, C; Factor, VM; Grunnet, M; Høgdall, D; Jensen, LH; Johansen, AZ; Johansen, JS; Larsen, OF; Linnemann, D; Mau-Sørensen, M; O'Rourke, CJ; Oliveira, DVNP; Wang, XW	1
Furuse, J; Hosoi, H; Ikeda, M; Kobayashi, S; Maeno, S; Morimoto, M; Morizane, C; Nagashima, F; Nakai, Y; Ojima, H; Okano, N; Okusaka, T; Ozaka, M; Sasaki, M; Takahara, N; Ueno, M; Yamanaka, T	1
Ban, D; Esaki, M; Furuse, J; Ioka, T; Ishii, H; Nara, S; Okusaka, T; Shimada, K; Takamoto, T	1
Lunec, J; Pan, YR; Wu, CE; Yeh, CN	1
Pan, YR; Wu, CE; Yeh, CN	1
Al-Toubah, TE; Cao, B; Centeno, BA; Kim, J; Kim, RD; Mehta, R; Tan, ES	1
Ando, M; Ando, Y; Ebata, T; Inada-Inoue, M; Maeda, O; Matsuoka, A; Mitsuma, A; Miyai, Y; Mizuno, T; Morita, S; Nagino, M; Shimokata, T; Sugishita, M; Takano, Y; Urakawa, H	1
Chen, LT; Chen, MH; Chiang, NJ; Shan, YS; Yeh, CN	1
Sardar, M; Shroff, RT	1
Brandi, G; Rizzo, A	2
Fukutomi, A; Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Kajiwara, T; Katanuma, A; Kobayashi, S; Komatsu, Y; Makino, K; Mizuno, N; Moriwaki, T; Morizane, C; Muto, M; Nakai, Y; Negoro, Y; Nemoto, N; Ozaka, M; Sakai, D; Shimizu, S; Tsuda, M; Tsuji, A; Ueno, M	1
Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T	1
Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Iwai, T; Kamata, K; Katanuma, A; Kataoka, T; Kato, N; Kawamoto, Y; Kojima, Y; Miyakawa, H; Miyamoto, A; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nishina, T; Okano, N; Okusaka, T; Oono, T; Ozaka, M; Sano, K; Shimizu, K; Shimizu, S; Shioji, K; Shirakawa, H; Sudo, K; Sugimori, K; Takahashi, H; Tobimatsu, K; Todaka, A; Ueno, M; Yamaguchi, H; Yamamoto, T; Yamashita, T; Yasuda, I	1
Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ	1
Abdelrahman, AM; Ahn, DH; Alva-Ruiz, R; Arora, M; Baker, AT; Barrett, MT; Bekaii-Saab, TS; Bogenberger, JM; Borad, MJ; Braggio, E; Buetow, KH; Chen, X; Dumbauld, CR; Egan, JB; Eskelinen, EL; Gamb, SI; Kosiorek, HE; Leiting, JL; Mansfield, AS; Meurice, N; Nagalo, BM; Roberts, LR; Salomao, MA; Serrano Uson Junior, PL; Sonbol, MB; Truty, MJ; Yonkus, J; Zhou, Y	1
Woo, SM	1
Kondo, N; Murakami, Y; Nakagawa, N; Sueda, T; Takahashi, S; Toyota, K; Uemura, K	1
Cao, Q; Duan, HX; Qu, GF; Tan, LH; Wang, LT; Xiao, S; Xiao, YP; Zhuang, X	1
Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N	1
Bréchon, M; Brezault, C; Brieau, B; Coriat, R; Dior, M; Dréanic, J; Goldwasser, F; Guillaumot, MA; Mir, O	1
Diness, LV; Larsen, FO; Markussen, A; Nielsen, D	1
Belkouz, A; Coelen, RJS; de Groot, JWB; Dierks, J; Gaspersz, MP; Groot Koerkamp, B; Klümpen, H; Meijer, WG; Otten, HM; Pruijt, JFM; Rentinck, M; Smit, JM; Ten Oever, D; Ten Tije, AJ; van Gulik, TM; van Spronsen, DJ; van Voorthuizen, T; van Vugt, JLA; Wilmink, JW	1
Bao, Y; Guo, H; Lu, Y; Qiu, L; Shi, Q; Sun, X; Wang, X; Yan, B	1
Ajavon-Hartmann, A; Alberts, SR; Genvresse, I; Grilley-Olson, JE; Kelly, A; Kim, RD; Peña, C; Xia, C	1
Aglietta, M; Aprile, G; Avallone, A; Cagnazzo, C; Cavalloni, G; Cereda, S; Doglioni, C; Fenocchio, E; Frattini, M; Gammaitoni, L; Leone, F; Martin, V; Nasti, G; Peraldo-Neia, C; Reni, M; Satolli, MA; Spadi, R; Venesio, T	1
Ojima, H; Okusaka, T; Sakamoto, Y; Tajimi, M; Tanizawa, Y; Yamagishi, S	1
Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N; Yamauchi, Y	1
Bo, X; Li, M; Liu, H; Ni, X; Shen, S; Suo, T; Wang, J; Wang, Y; Xu, J	1
Abdel-Rahman, O; Elhalawani, H; Elsayed, Z	1
Anthoney, A; Backen, AC; Beare, S; Bridgewater, JA; Corrie, PG; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; McNamara, MG; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS	1
Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Okumura, Y; Sakamoto, T; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H; Yamada, D	1
Chang, HM; Hyung, J; Jeong, JH; Kim, B; Kim, KP; Ryoo, BY; Yoo, C	1
Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K	1
Ajiki, T; Gotoh, K; Hatano, E; Hirose, T; Ikai, I; Ioka, T; Kamei, K; Kobayashi, S; Morita, S; Nagano, H; Sakai, D; Satake, H; Seo, S; Terajima, H; Tohyama, T; Tomokuni, A; Uchida, Y	1
Balachandar, V; Devi, SM; Kaavya, J; Mahalaxmi, I; Santhy, KS	1
Cloyd, JM; Pawlik, TM	1
Massarweh, NN; Tran Cao, HS	1
Hwang, JH; Kim, H; Kim, J; Kim, JW; Kim, YT; Lee, JC; Lee, SH; Paik, WH; Ryu, JK	1
Abou-Alfa, GK; Berger, M; Bradley, M; Capanu, M; Cercek, A; Chou, JF; Dika, IE; Gerst, S; Harding, JJ; Hollywood, E; Lowery, MA; Morgono, E; O'Reilly, EM; Ptashkin, R; Rasalan-Ho, T; Salehi, E; Valentino, E; Wong, P; Yu, KH; Zehir, A	1
Bang, S; Chung, MJ; Jo, JH; Kang, H; Lee, HS; Park, JY; Park, SW; Song, SY	1
Ehrlich, A; Foerster, F; Galle, PR; Maderer, A; Marquardt, JU; Moehler, M; Nickolay, T; Ruckes, C; Schad, A; Sivanathan, V; Thomaidis, T; Weinmann, A; Woerns, M	1
Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A	1
Fischer, M; Kirstein, MM; Kratzel, AM; Manns, MP; Mederacke, YS; Schweitzer, N; Vogel, A	1
Choi, HJ; Hong, JH; Jang, JS; Kang, JH; Kim, MJ; Kim, S; Kim, ST; Lee, HW; Lee, J; Lee, MA; Lim, HY; Oh, SY; Park, JO; Park, YS; Sohn, BS; Yoon, SY	1
Bachini, M; Bekaii-Saab, T; Crane, C; Edeline, J; El-Khoueiry, A; Feng, M; Katz, MHG; Kennedy, EB; Maithel, SK; Primrose, J; Shroff, RT; Soares, HP; Valle, J	1
Bauernhofer, T; Gerger, A; Kasparek, AK; Moik, F; Pichler, M; Posch, F; Prinz, F; Reicher, A; Riedl, JM; Rossmann, CH; Schaberl-Moser, R; Stöger, H; Stotz, M; Szkandera, J; Terbuch, A; Winder, T	1
Goff, LW; Roth, MT	1
Franses, JW; Hong, TS; Zhu, AX	1
Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H	1
Ando, T; Kameda, R; Kobayashi, S; Ohkawa, S; Ueno, M	1
Fang, JY; Sun, TT; Wang, JL	1
Ciombor, KK; Goff, LW	1
Amano, R; Hirakawa, K; Kimura, K; Murata, A; Nakata, B; Yamada, N; Yashiro, M	1
Boku, N; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Mizusawa, J; Morizane, C; Okusaka, T; Takashima, A; Ueno, M	1
Hatano, E; Ishii, T; Kanai, M; Machimoto, T; Nagata, H; Narita, M; Tanaka, S; Taura, K; Uemoto, S; Yamamoto, K; Yamanaka, K	1
Chen, YJ; Hu, JB; Li, HB; Wang, B; Yang, R; Zou, SQ	1
Ajiki, T; Awane, M; Furuyama, H; Ikai, I; Ikezawa, K; Ioka, T; Kanai, M; Kou, T; Kume, M; Kuroda, N; Miyamoto, A; Nagano, H; Ochiai, T; Ogawa, M; Taira, K; Takeda, Y; Takemura, S; Terajima, H; Toyokawa, H; Tsukamoto, T; Yazumi, S	1
Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH	1
Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z	1
Akiyama, D; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N	1
Dong, J; He, S; Liu, L; Shen, J; Sun, X	1
Daignault, S; Healy, P; O'Malley, M; Ramnath, N	1
Arakawa, K; Ide, M; Ishioka, NS; Itoh, H; Kaira, K; Kanai, Y; Mori, M; Nagamori, S; Ogawa, T; Ohshima, Y; Oriuchi, N; Oyama, T; Segawa, A; Shimizu, K; Sunaga, N; Sunose, Y; Takeyoshi, I; Tominaga, H; Yamaguchi, A	1
Donahue, TR; Elashoff, DA; Farrell, JJ; Gorgan, TR; Hines, OJ; Wei, CH	1
Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH	1
Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU	1
Bang, SM; Chung, JB; Kang, DR; Kim, KS; Park, JY; Park, MS; Park, SW; Seong, J; Song, SY; Yi, SW	1
Braghiroli, MI; da Costa Miranda, V; Faria, LD; Hoff, PM; Riechelmann, RP; Sabbaga, J; Siqueira, SA	1
Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM	1
Hakamada, K; Ishido, K; Ishiguro, A; Kimura, N; Kudo, D; Sato, A; Takahata, T; Toyoki, Y; Wakiya, T; Yakoshi, Y	1
Ajiki, T; Fujiwara, Y; Hatano, E; Ikoma, H; Ioka, T; Kaihara, S; Kanai, M; Kobayashi, S; Miyamoto, A; Morita, S; Nagano, H; Nakamori, S; Sakai, D; Takemura, S; Terajima, H; Toyoda, M; Toyokawa, H; Tsuji, A	1
Harada, N; Ikeda, T; Ikegami, T; Kawanaka, H; Maehara, Y; Matsuura, H; Morita, M; Okadome, K; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Uchiyama, H; Yamashita, Y; Yoshizumi, T	1
Alabiso, O; Bajetta, E; Bertolini, A; Buzzoni, R; Cantore, M; Ciarlo, A; De Braud, F; Iannacone, C; Mambrini, A; Mazzaferro, V; Platania, M; Pusceddu, S; Turco, C	1
Choi, DW; Choi, JY; Choi, MK; Choi, SH; Heo, JS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, YS	1
Adhikaree, J; Madhusudan, S	1
Abrams, TA; Allen, JN; Baran, A; Blaszkowsky, LS; Borger, DR; Clark, JW; Connolly, GC; Faris, JE; Fuchs, C; Goyal, L; Harris, DJ; Herr, M; Hezel, AF; Hyrien, O; Iafrate, AJ; Khorana, AA; Murphy, JE; Ng, K; Noel, MS; Regan, E; Ryan, DP; Sheehan, S; Yurgelun, M; Zheng, H; Zhu, AX	1
Goda, Y; Irie, K; Kobayashi, S; Morimoto, M; Ohkawa, S; Ueno, M	1
Ajiki, T; Eguchi, H; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kubo, S; Morita, S; Nagano, H; Sakai, D; Seo, S; Takemura, S; Taura, K; Terajima, H; Toyokawa, H; Tsuji, A; Yanagimoto, H	1
Braddock, M; Chen, YP; Lin, YQ; Shi, KQ; Wang, LR; You, J; Zheng, MH; Zhu, GQ; Zou, H	1
Bonnetain, F; Borg, C; Demarchi, M; Fein, F; Fiteni, F; Kim, S; Nguyen, T; Paillard, MJ; Pivot, X; Vernerey, D	1
Bennouna, J; Bonnet, I; Chauffert, B; Fauchart, JP; Gasmi, M; Jouve, JL; Le Malicot, K; Lepage, C; Maingon, P; Martin, P; Michel, P; Morin, T; Phelip, JM; Rostain, F; Seitz, JF; Smith, D; Subtil, F; Vendrely, V	1
Hwang, IG; Jang, JS; Lee, KH; Lee, KT; Lee, MA; Lim, J; Nam, EM; Song, HS; Zang, DY	1
Eckel, F; Schmid, RM	2
Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K	1
Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S	1
Ajiki, T; Fujiwara, Y; Hatano, E; Ikoma, H; Ikuta, S; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Kubo, S; Marubashi, S; Miyamoto, A; Morita, S; Nagano, H; Sakai, D; Seo, S; Shiomi, H; Terajima, H; Yanagimoto, H	1
Ajiki, T; Eguchi, K; Furuse, J; Hakamada, K; Ichikawa, W; Ikeda, M; Ioka, T; Ishii, H; Maguchi, H; Matsuyama, M; Miyazaki, M; Mizuno, N; Ohashi, Y; Ohkawa, S; Sasaki, Y; Yamaguchi, T; Yamamoto, M; Yamaue, H	1
Aktas, B; Balakan, O; Berk, V; Cinkir, Hy; Demirci, U; Helvaci, K; Kos, T; Kucukoner, M; Oztop, I; Sevinc, A; Tonyali, O; Turan, N; Unal, OU; Yildiz, R; Yilmaz, AU	1
Arrivas Bajardi, E; Barone, C; Bencardino, K; Buonadonna, A; Cartenì, G; Comandone, A; Ferrari, D; Ferrari, S; Foa, P; Gebbia, V; Milella, M; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Testa, A; Tronconi, MC; Zaniboni, A	1
Li, ZH; Liu, H; Lu, LG; Zhang, QD; Zhang, QQ	1
Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Koike, K; Maetani, I; Maguchi, H; Matsubara, S; Mukai, T; Nakai, Y; Okabe, Y; Sasaki, T; Toda, N; Yagioka, H; Yasuda, I	1
Shibata, Y	1
Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY	1
Bai, LY; Chang, IC; Chang, JY; Chao, Y; Chen, JS; Chen, LT; Chiang, NJ; Chiu, CF; Ho, CL; Hsieh, RK; Hsu, C; Huang, SF; Lee, KD; Rau, KM; Shan, YS; Shiah, HS; Tsai, CS; Tsou, HH; Yang, Y; Yen, CJ; Yu, MS	1
Uwagawa, T; Yanaga, K	1
Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH	1
Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M	1
Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Nakashima, S; Tomimaru, Y; Tomokuni, A; Wada, H	1
Galluzzo, A; Hayano, K; Sahani, DV; Zhu, AX	1
Cho, M; Fournier, C; Gao, F; Linehan, D; Myerson, R; Nagaraj, G; Parikh, P; Picus, J; Sorscher, S; Strasberg, S; Suresh, R; Tan, BR; Wang-Gillam, A	1
Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G	1
Furuse, J; Naruge, D	1
Amano, R; Hirakawa, K; Kimura, K; Murata, A; Yamazoe, S	1
Morizane, C; Okusaka, T	1
Araki, M; Endo, S; Hamano, Y; Hasegawa, N; Hyodo, I; Imanishi, M; Ishida, H; Ito, Y; Kobayashi, M; Moriwaki, T; Sato, D; Shimoyamada, M; Sugaya, A; Yoshida, S	1
Choi, J; Choi, Y; Haam, S; Huh, YM; Kim, HO; Lee, DK; Noh, I	1
Imaizumi, H; Iwai, T; Kaneko, T; Kida, M; Koizumi, W; Miyazawa, S; Okuwaki, K; Takezawa, M; Watanabe, A; Yamauchi, H	1
Bridgewater, J; Furuse, J; Grenader, T; Mizuno, N; Nash, S; Okusaka, T; Plotkin, Y; Valle, J; Wasan, H	1
Bachet, JB; Boussaha, T; Brieau, B; Cacheux, W; Claudez, P; Coriat, R; Dahan, L; De Rycke, Y; Desrame, J; Lecomte, T; Lièvre, A; Marthey, L; Mary, F; Soibinet, P; Taieb, J; Thirot-Bidault, A; Tougeron, D; Trouilloud, I; Vasseur, P; Zaanan, A	1
Benafif, S; Bridgewater, J; Lamarca, A; Ross, P; Valle, JW	1
Furukawa, K; Sakamoto, T; Shiba, H; Tsutsumi, J; Uwagawa, T; Yanaga, K	1
Anthoney, DA; Backen, AC; Beare, S; Bridgewater, JA; Corrie, P; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; Morris, K; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS	1
Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS	1
Asano, T; Cho, A; Furukawa, D; Kainuma, O; Miura, F; Nakagohri, T; Sano, K; Yamamoto, H	1
Furukawa, K; Kato, A; Kishimoto, T; Miyazaki, M; Nakadai, E; Nakatani, Y; Ohtsuka, M; Shimizu, H; Takayashiki, T; Yoshidome, H; Yoshitomi, H	1
Hoegdall, E; Nielsen, D; Ole Larsen, F; Taksony Solyom Hoegdall, D	1
Bae, K; Han, SS; Hong, EK; Jung, MK; Kim, TH; Koh, YH; Lee, WJ; Park, SJ; Park, WS; Woo, SM; Yoon, KA	1
Akiyama, T; Fujimori, N; Funakosi, A; Hisano, T; Horiuchi, H; Ito, T; Kawabe, K; Okabe, Y; Sirabe, K; Suga, H; Ueki, T; Yamaguchi, H; Yamashita, Y	1
Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM	1
Aglietta, M; Amatu, A; Aprile, G; Belli, C; Cagnazzo, C; Cereda, S; Ciuffreda, L; Fasola, G; Filippi, R; Leone, F; Marino, D; Montano, M; Nasti, G; Reni, M; Siena, S; Spadi, R	1
Akita, H; Gotoh, K; Ishikawa, O; Kobayashi, S; Marubashi, S; Nishiyama, K; Ohigashi, H; Sakon, M; Takahashi, H; Teshima, T; Tomokuni, A; Yamada, T; Yano, M	1
Ando, Y; Ebata, T; Fujita, K; Maeda, O; Mitsuma, A; Nagino, M; Sasaki, Y; Shibata, T; Shimokata, T	1
Ajiki, T; Fujiwara, Y; Hamada, A; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Minami, H; Nagano, H; Takashima, Y; Toyoda, M; Yoshimura, K	1
Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H	1
Aprile, G; Brandi, G; Caparello, C; Cereda, S; Falcone, A; Fornaro, L; Leone, F; Lonardi, S; Milella, M; Musettini, G; Pasquini, G; Santini, D; Silvestris, N; Sperduti, I; Vasile, E; Vivaldi, C	1
Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C	1
Doherty, M; Hedley, D; Knox, JJ; McNamara, MG; Mian, M; Serra, S	1
Beare, S; Bridgewater, J; Duggan, M; Lee, D; Lopes, A; McEntee, D; Ricamara, M; Sukumaran, A; Valle, JW; Wasan, H	1
Fukuda, H; Furuse, J; Ishii, H; Katayama, H; Mizusawa, J; Morizane, C; Okusaka, T	1
Endo, S; Gosho, M; Hyodo, I; Kobayashi, M; Moriwaki, T; Sugaya, A; Yamada, T; Yamamoto, Y	1
Andrikou, K; Bianconi, M; Bittoni, A; Brunetti, O; Casadei Gardini, A; Cascinu, S; Del Prete, M; Dessì, A; Faloppi, L; Giampieri, R; Lai, E; Santini, D; Scartozzi, M; Silvestris, N; Valgiusti, M	1
Chao, Y; Chen, JS; Chen, LT; Chen, MH; Chiang, NJ; Hsu, C; Huang, SF; Shan, YS; Shen, YY; Tsou, HH; Yeh, TS	1
Aiken, C; Cronk, M; Ferraro, D; Gebski, VJ; Goldstein, D; Grimison, P; Karapetis, CS; Lipton, LL; McLachlan, S; Ng, S; O'Connell, RL; Shannon, J; Sjoquist, KM; Tebbutt, NC; Vasey, P; Zalcberg, JR	1
Ahn, CW; Ahn, DH; Bekaii-Saab, T; Chen, JL; Ciombor, K; Jain, A; Javle, M; Mikhail, S; Noonan, AM; Shroff, RT; Wu, C	1
Bang, S; Cha, J; Kim, HM; Lee, KJ; Park, SW; Seong, J; Song, SY; Yi, SW	1
Chang, HM; Kim, KP; Park, K; Park, S	1
Arakawa, I; Ejiri, M; Inoue, T; Matsuura, K; Nakao, H; Saito, H; Tsukiyama, I; Yamamoto, Y; Yoneda, M	1
Grande, C; Groman, A; Iancu, DM; Iyer, RV; Ma, WW; Malhotra, U; Pokuri, VK; Saab, TB	1
Akita, H; Fujiwara, Y; Fukui, K; Gotoh, K; Kobayashi, S; Marubashi, S; Sakon, M; Takahashi, H; Teshima, T; Tomokuni, A; Yamada, T	1
Akiyama, D; Isayama, H; Ishigaki, K; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Uchino, R; Yagioka, H	1
Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M	1
Brenner, WS; Fournier, C; Fracasso, PM; Gao, F; James, J; Marsh, S; McLeod, HL; Picus, J; Tan, BR; Yen-Revollo, JL	1
Ide, T; Kitajima, Y; Kohya, N; Mitsuno, M; Miyazaki, K; Ohtaka, K; Sato, K	1
Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F	1
Furuse, J	2
Aikawa, I; Matsuda, T; Minato, H; Shikata, S	1
Alberts, SR; Fitch, TR; Foster, NR; Jaslowski, AJ; Kugler, JW; McWilliams, RR; Quevedo, FJ; Sande, JR	1
Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, MJ; Kim, TY; Lee, SH; Oh, DY	1
Bae, SB; Cheon, YG; Cho, YD; Hong, DS; Kim, CK; Kim, HJ; Kim, YS; Lee, KT; Lee, NS; Lee, SC; Moon, JH; Park, HS; Park, SH; Park, SK; Won, JH	1
Mayo, MS; Smith, HJ; Watkins, JF; Williamson, SK	1
André, T; Clemens, MR; Fartoux, L; Leslie, M; Louvet, C; Mehmud, F; Perez, N; Reyes-Vidal, JM; Rosmorduc, O; Ross, P; Scheithauer, W	1
Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I	1
Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M	1
Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS	1
Cantore, M; Danesi, R; Del Freo, A; Del Tacca, M; Giovannetti, E; Mambrini, A; Nannizzi, S; Orlandi, M; Pacetti, P; Tartarini, R	1
Doi, R; Fukushima, M; Hatano, E; Ikai, I; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Misawa, A; Morita, S; Nishimura, T; Sasaki, T; Yanagihara, K; Yasuda, H; Yazumi, S	1
Amitani, R; Hatano, K; Ikeda, A; Kawakami, H; Kimura, T; Kita, R; Maruo, T; Matsuo, H; Nakatsuji, M; Nishijima, N; Nishikawa, H; Okabe, Y; Osaki, Y; Saito, S; Tsumura, T	1
Bisegna, R; Bonfili, P; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F; Sica, G; Tombolini, V	1
Byun, JH; Hwang, IG; Jang, JS; Kim, BS; Kim, SY; Kim, YH; Lee, KH; Lee, MA; Lee, SJ; Lim, HY; Oh, SC; Oh, SJ; Park, E; Song, HS; Yoo, N; Yoon, S	1
Anthoney, A; Baka, S; Bridgewater, J; Corrie, P; Dixon, L; Evans, L; Falk, S; Gollins, S; Highley, M; Iveson, T; Johnson, P; Jones, E; Lofts, F; Maraveyas, A; Meyer, T; Osborne, R; Swindell, R; Valle, JW; Wasan, H	1
Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I	1
Boku, N; Endo, M; Igawa, S; Murakami, H; Nakamura, Y; Shukuya, T; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N	1
Abrams, TA; Allen, JN; Bhargava, P; Blaszkowsky, LS; Chan, JA; Clark, JW; Enzinger, PC; Fuchs, CS; Horgan, K; Jain, SR; Kambadakone, AR; Kwak, EL; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Sahani, DV; Sheehan, S; Stuart, K; Zheng, H; Zhu, AX	1
Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K	1
Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S	1
Esaki, M; Hiraoka, N; Hirohashi, S; Ino, Y; Kanai, Y; Kokubu, A; Kondo, T; Kosuge, T; Miyamoto, M; Morofuji, N; Nara, S; Ojima, H; Okusaka, T; Onaya, H; Sakamoto, Y; Shibata, T; Shimada, K; Shimizu, H; Yoshikawa, D	1
Kaley, K; Lee, MX; Li, J; Merl, M; Saif, MW	1
Aldrighetti, L; Cereda, S; Nicoletti, R; Passoni, P; Reni, M; Viganò, MG; Villa, E	1
Bossone, G; Cognetti, F; Gelibter, AJ; Marolla, P; Milella, M; Pino, MS; Sperduti, I	1
Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY	1
Anthoney, A; Bridgewater, J; Cunningham, D; Hughes, S; Iveson, T; Madhusudan, S; Maraveyas, A; Palmer, DH; Pereira, SP; Roughton, M; Valle, J; Wasan, H	1
Mayer, RJ; Wolpin, BM	1
Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T	1
Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P	1
Abdi, E; Ackland, SP; Brown, C; Gainford, MC; Gebski, V; Goldstein, D; Jefford, M; Miller, D; Selva-Nayagam, S; Shannon, J; Tebbutt, N; van Hazel, G	1
Bouché, O; Cattan, S; Hebbar, M; Heurgue, A; Hollebecque, A; Lagarde, S; Mariette, C; Pruvot, FR; Romano, O; Scaglia, E; Triboulet, JP; Zerbib, P	1
Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y	1
Baldi, GG; Caraglia, M; Cass, CE; Catalano, V; Chiusa, L; Falcone, A; Giacobino, A; Lai, R; Mackey, J; Manazza, AD; Rizzo, S; Russo, A; Santini, D; Schiavon, G; Tonini, G; Vasile, E; Vincenzi, B	1
Hirano, K; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y	1
Fukutomi, A; Funai, J; Funakoshi, A; Furuse, J; Kondo, S; Koshiji, M; Miyazaki, M; Mizuno, N; Nagaoka, S; Nagino, M; Nakachi, K; Nambu, Y; Nimura, Y; Ohkawa, S; Okusaka, T	1
Fukuda, H; Furuse, J; Ishii, H; Morizane, C; Nakamura, K; Okusaka, T; Takashima, A	1
Cariati, A	1
Hall, FM	1
Fournier, CC; James, JS; Picus, J; Suresh, R; Tan, BR; Trinkhaus, K; Williams, KJ	1
Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Kohya, N; Miyazaki, K; Nakamura, J; Noshiro, H; Ohtaka, K; Tokunaga, O	1
Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K	1
Scheithauer, W	2
Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y	1
Ishii, H; Kamei, A; Kuraoka, K; Matsuyama, M; Ozaka, M; Takano, K; Yukisawa, S	1
Christos, P; Espinoza-Delgado, I; Hamel, N; Kaubish, A; Lane, ME; Matulich, D; Ocean, AJ; Siegel, A; Sparano, JA; Sung, M; Ward, MM; Yen, Y	1
Ebrahim, MA; Halim, A; Saleh, Y	1
Furuse, J; Hagihara, A; Ikeda, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Shimizu, S; Suzuki, E; Ueno, H	1
Freimann-Pircher, S; Gruenberger, B; Gruenberger, T; Heubrandtner, U; Kaczirek, K; Roka, R; Schueller, J; Tamandl, D; Wrba, F	1
Aglietta, M; Bardelli, A; Casorzo, L; Cavalloni, G; Chiorino, G; Leone, F; Migliardi, G; Penachioni, JY; Peraldo-Neia, C; Pignochino, Y; Risio, M; Sarotto, I	1
Bridgewater, J; Furuse, J; Koshiji, M; Okusaka, T; Taketsuna, M; Valle, J; Wasan, H	1
Heike, Y; Ikeda, M; Kaida, M; Kojima, Y; Kondo, S; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Takaue, Y; Ueno, H; Wakeda, T; Yamaki, Y	1
Carlson, JJ; Roth, JA	1
Hezel, AF; Zhu, AX	2
Bridgewater, J; Vazquez, I	1
Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H	1
Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP	1
Bang, S; Chung, JB; Chung, MJ; Kim, YJ; Park, JY; Park, SW; Song, SY	1
Copur, MS; Obermiller, A	1
Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Sato, T; Sato, Y; Sonoda, T; Takimoto, R; Yoshida, M	1
Jensen, LH	1
Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM	1
Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, TY; Min, AR; Nam, HJ; Oh, DY; Song, SH; Yoon, YK	1
Hasegawa, Y; Itou, N; Nishizuka, S; Nitta, H; Takahara, T; Takahashi, M; Wakabayashi, G	1
Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D	1
Konishi, M	1
Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K	1
Heike, Y; Okusaka, T; Sato, T; Ueno, M	1
Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V	1
Hansen, TF; Jakobsen, A; Jensen, LH; Lindebjerg, J; Ploen, J	1
Fukutomi, A; Furuse, J; Koshiji, M; Miyazaki, M; Nimura, Y; Okusaka, T; Taketsuna, M	1
Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Takasu, A	1
Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H	1
Abe, T; Akada, T; Dendo, M; Ito, Y; Kato, H; Muto, R; Nakanishi, C; Ozawa, Y; Sakashita, K; Sato, K	1
Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW	1
Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Durand, JP; Goldwasser, F; Mir, O; Perkins, G; Ropert, S	1
Bertetto, O; Ceccarelli, M; Chiappino, I; Ciccone, G; Ciuffreda, L; Giacobino, A; Napoletano, R; Novarino, AM; Satolli, MA; Schena, M	1
Hirakata, A; Makino, H; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Suzuki, S; Uchida, E; Yokoyama, T; Yoshida, H	1
Andou, T; Kameda, R; Kobayashi, S; Morinaga, S; Ohkawa, S; Ueno, M; Yamamoto, N	1
Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM	1
Kobayashi, N; Nishiuma, S; Okubo, S; Taketsuna, M; Taniai, H	1
Pereira, S	1
Cao, P; Chen, E; Green, DE; Hedley, DW; Ibrahimov, E; Knox, JJ; McNamara, MG; Metran-Nascente, C; Serra, S; Tsao, M; Vines, D; Xu, J	1
Bischoff, S; Caca, K; Kubicka, S; Nehls, O; Pelzer, U; Riess, H; Sinn, M; Stieler, JM; von Weizsäcker, F	1
Fujita, T; Imataki, O; Matsunaga, T; Nishiuchi, T; Ohnishi, H; Okutani, Y; Shimizu, H; Shimizu, T; Yamagishi, Y	1
Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM	1
Doki, Y; Eguchi, H; Ishii, H; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Wada, H; Yamada, D	1
Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N	1
Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Kogure, H; Koike, K; Maetani, I; Maguchi, H; Mukai, T; Nakai, Y; Okabe, Y; Sasahira, N; Sasaki, T; Toda, N; Yasuda, I	1
Eichelmann, K; Fahlke, J; Hribaschek, A; Kuhn, R; Ridwelski, K; Rudolph, S	1
Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M	1
Boxberger, F; Brueckl, V; Brueckl, WM; Hahn, EG; Hautmann, M; Hohenberger, W; Jüngert, B; Wein, A	1
Awasthy, BS; Doval, DC; Gupta, S; Gupta, SK; Sekhon, JS	1
Okusaka, T	1
Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO	1
Haller, D; Sun, W	1
Bhargava, P; Jani, CR; O'Donnell, JL; Rocha Lima, CM; Savarese, DM; Stuart, KE	1
Gennatas, K; Gouveris, P; Karatzas, G; Kosmas, C; Margaris, H; Mouratidou, D; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Tsavaris, N; Tsipras, H; Tzima, E	1
Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B	1
Chen, JS; Cheng, AL; Hsu, C; Hsu, CH; Li, CC; Liu, HT; Lu, YS; Shen, YC; Wu, CY; Yang, CH; Yeh, KH	1
André, T; Avenin, D; de Gramont, A; Gayet, B; Hannoun, L; Houry, S; Lotz, JP; Louvet, C; Maindrault-Goebel, F; Paye, F; Provent, S; Rosmorduc, O; Selle, F; Tournigand, C	1
Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE	1
Charoentum, C; Moonprakan, S; Napapan, S; Thongprasert, S	1
Jin-Kim, H; Kim, JS; Kim, SH; Kim, YH; Kwon, HC; Oh, SY; Park, JS	1
Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; von Delius, S	1
Bria, E; Carboni, F; Carlini, P; Cognetti, F; Di Cosimo, S; Ettorre, GM; Gelibter, A; Giannarelli, D; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E	1
Funakoshi, A; Ishii, H; Ohkawa, S; Okusaka, T; Saito, H; Saito, S; Tsuyuguchi, T; Yamao, K	1
Fujisaki, S; Kayashima, S; Nemoto, N; Oimuna, T; Takashina, M; Takayama, T; Tomita, R	1
Chang, YS; Cho, JY; Chung, JB; Lee, DK; Lee, SJ; Paik, YH; Park, MS; Song, SY; Yoon, DS; Yu, JS	1
Bang, SM; Cho, EK; Lee, JH; Lee, JN; Park, SH; Park, YH; Shin, DB	1
Funakoshi, A; Sumii, T	1
Arii, S; Nakamura, N; Teramoto, K	1
Ikeda, M; Morizane, C; Okusaka, T; Ueno, H	1
Choi, SH; Heo, JS; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KT; Park, JO; Park, K; Park, YS	1
Berrios, M; Cordova, A; de Aretxabala, X; Gallardo, J; Hepp, J; Leon, J; Maluenda, F; Roa, I; Roa, JC	1
Bang, S; Choi, JS; Chung, JB; Kim, KS; Kim, YJ; Lee, WJ; Park, BK; Park, JY; Park, SW; Song, SY	1
Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cillo, U; Cingarlini, S; Farinati, F; Marchese, F; Mattiazzi, M; Pastorelli, D; Salmaso, F; Sanavio, C; Zanus, G; Zovato, S; Zustovich, F	1
Tsukagoshi, S	1
Geissler, M; Harder, J; Henss, H; Kummer, O; Lohrmann, C; Opitz, O; Otto, F; Riecken, B; Usadel, H	1
Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS	1
D'Andrea, MR; Falci, C; Monfardini, S; Pasetto, LM	1
Doi, E; Doi, R; Fukushima, M; Hatano, E; Ikai, I; Ishiguro, H; Kiba, T; Kitano, T; Matsumoto, S; Mori, A; Nishimura, T; Teramukai, S; Yanagihara, K; Yasumi, S; Yoshikawa, K	1
Ahn, MJ; Kim, HK; Kim, JS; Kim, TY; Lee, J; Lee, MA; Lee, NS; Lim, HY; Park, BJ	1
Danenberg, PV; Endo, I; Fujii, Y; Ichikawa, Y; Ishikawa, T; Matsuyama, R; Mori, R; Shimada, H; Taniguchi, K; Togo, S; Ueda, M	1
Chin, SN; Knox, JJ; Pond, GR; Riechelmann, RP; Townsley, CA	1
Bluethner, T; Caca, K; Moebius, C; Mossner, J; Niederhagen, M; Serr, F; Wiedmann, M; Witzigmann, H	1
André, T; Blanchard, P; Huguet, F	1
Cantore, M; Del Freo, A; Fiorentini, G; Mambrini, A; Orlandi, M; Pacetti, P; Torri, T	1
Blum, HE; Harder, J; Kummer, O; Olschewski, M; Opitz, O; Otto, F	1
Haller, DG; Hershock, D; Hewitt, MR; Sun, W; Theobald, MR	1
Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Saisho, H; Sato, T; Tanaka, K; Yamao, K; Yonemoto, N	1
Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J	1
Hatakeyama, K; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Toshima, M; Wakai, T	1
Gerson, R; Serrano, A	1
Germano, D; Manzione, L; Romano, R	1
Bareck, E; Brodowicz, T; Hejna, MH; Kornek, GV; Lang, F; Lenauer, J; Raderer, M; Scheithauer, W; Valencak, JB; Weinländer, GS	1
Alabiso, O; Bortolini, M; Botta, M; Buosi, R; Chiappino, I; Clara, R; Grosso, M; Mussa, A; Satolli, A; Zai, S; Zanon, C	1
Abruzzo, F; Di Leo, R; Mandina, P; Scarpulla, M; Verderame, F	1
Depisch, D; Fiebiger, W; Kornek, GV; Krauss, G; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H	1
Assmann, G; Eckel, F; Lersch, C; Schulte-Frohlinde, E	1

Reviews

51 review(s) available for deoxycytidine and Biliary Tract Neoplasms

Article	Year
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. European journal of cancer (Oxford, England : 1990), 2022, Volume: 164 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic	2022
Bulletin du cancer, 2022, Volume: 109, Issue:11S Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2022
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer. Future oncology (London, England), 2023, Volume: 19, Issue:34 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2023
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer. Targeted oncology, 2023, Volume: 18, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Humans; Systematic Reviews as Topic	2023
Durvalumab: A Review in Advanced Biliary Tract Cancer. Targeted oncology, 2023, Volume: 18, Issue:6 Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome	2023
Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Neoplasm Staging; Receptor, Fibroblast Growth Factor, Type 2	2019
[Adjuvant treatment of biliary tract cancers: Who and how?] Bulletin du cancer, 2020, Volume: 107, Issue:1 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome	2020
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. Medical oncology (Northwood, London, England), 2020, Jun-11, Volume: 37, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome	2020
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. Current opinion in oncology, 2020, Volume: 32, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Multicenter Studies as Topic; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Tegafur	2020
Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis. Oncology research and treatment, 2020, Volume: 43, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult	2020
Systemic treatment options for advanced biliary tract carcinoma. Journal of gastroenterology, 2020, Volume: 55, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Molecular Targeted Therapy; Mutation; Prognosis	2020
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. Japanese journal of clinical oncology, 2020, Dec-16, Volume: 50, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur	2020
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. Biomolecules, 2020, 10-23, Volume: 10, Issue:11 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Tumor Suppressor Protein p53	2020
Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules, 2021, 01-13, Volume: 11, Issue:1 Topics: Biliary Tract Neoplasms; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Molecular Targeted Therapy	2021
Biliary cancer: gateway to comprehensive molecular profiling. Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Leucovorin; Mutation; Oncogene Proteins, Fusion; Organoplatinum Compounds; Survival Rate	2021
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!" Cancer treatment and research communications, 2021, Volume: 27 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Neoplasm Staging; Progression-Free Survival; Randomized Controlled Trials as Topic	2021
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer treatment and research communications, 2021, Volume: 27 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Review Literature as Topic; Standard of Care	2021
[Chemotherapy for Biliary Tract Cancer]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2017, Mar-25, Volume: 69, Issue:3 Topics: Antineoplastic Agents; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin	2017
Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2017, Volume: 37, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2017
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. The Cochrane database of systematic reviews, 2018, Apr-06, Volume: 4 Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur	2018
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route? Journal of cellular physiology, 2019, Volume: 234, Issue:6 Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction	2019
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 04-20, Volume: 37, Issue:12 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Oxaliplatin; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies	2019
Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Survival	2013
Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis. Anti-cancer drugs, 2013, Volume: 24, Issue:8 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Evidence-Based Medicine; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome	2013
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas, 2013, Volume: 42, Issue:8 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins	2013
[A case of unresectable biliary tract cancer with liver metastasis that exhibited an effective response to chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Stents	2013
Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:7 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans	2014
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer medicine, 2014, Volume: 3, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic	2014
Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis. World journal of gastroenterology, 2014, Dec-21, Volume: 20, Issue:47 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Odds Ratio; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome	2014
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surgery today, 2015, Volume: 45, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome	2015
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy. British journal of cancer, 2016, Apr-12, Volume: 114, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome	2016
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Current cancer drug targets, 2011, Volume: 11, Issue:1 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Immunohistochemistry	2011
Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Critical reviews in oncology/hematology, 2011, Volume: 80, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Treatment Outcome	2011
Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:2 Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins	2011
Nonsurgical therapy of biliary tract cancer. Current opinion in gastroenterology, 2011, Volume: 27, Issue:3 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Photochemotherapy	2011
Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome	2012
Role of chemotherapy in treatments for biliary tract cancer. Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome	2012
Review of gemcitabine in biliary tract carcinoma. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 20 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans	2002
Chemotherapy in biliary tract carcinomas: results in India. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 20 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; India	2002
Chemotherapy for biliary tract cancer in Japan. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 20 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Japan	2002
[Chemotherapy for biliary tract cancers: general remarks]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Clinical Trials as Topic; Cytarabine; Deoxycytidine; Doxorubicin; Drug Therapy; Gemcitabine; Humans; Tegafur; Treatment Outcome	2006
[Systemic chemotherapy with gemcitabine for advanced biliary tract carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 1 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Treatment Outcome	2006
[5 -fluoropyrimidines for treatment of biliary tract cancers]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Pyridines; Pyrimidines; Tegafur; Uracil	2006
Chemoradiotherapy in gallbladder cancer. Journal of surgical oncology, 2006, Jun-15, Volume: 93, Issue:8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Palliative Care; Survival Analysis	2006
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome	2006
[Gemcitabine is an effective single agent for the treatment of advanced biliary tract cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Survival Rate	2006
Gemcitabine in advanced biliary tract cancers. Critical reviews in oncology/hematology, 2007, Volume: 61, Issue:3 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Neoplasm Staging; Palliative Care; Radiotherapy, Adjuvant	2007
Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology, 2006, Volume: 70, Issue:5 Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome	2006
[Gemcitabine and digestive carcinomas]. Bulletin du cancer, 2007, Volume: 94 Spec No Actualites Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Digestive System Neoplasms; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms	2007
Systemic therapy for biliary tract cancers. The oncologist, 2008, Volume: 13, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome	2008
Chemotherapy with gemcitabine in advanced biliary tract carcinoma. Reviews on recent clinical trials, 2008, Volume: 3, Issue:1 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Gemcitabine; Humans	2008

Trials

150 trial(s) available for deoxycytidine and Biliary Tract Neoplasms

Article	Year
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 01-20, Volume: 40, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Time Factors	2022
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 06-01, Volume: 28, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Ramucirumab; Vascular Endothelial Growth Factor Receptor-2	2022
Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study. Nature reviews. Gastroenterology & hepatology, 2022, Volume: 19, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Immunotherapy; Treatment Outcome	2022
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-03, Volume: 28, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chromatin Assembly and Disassembly; Deoxycytidine; Gemcitabine; Humans; Nivolumab	2022
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. British journal of cancer, 2022, Volume: 127, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mitogen-Activated Protein Kinase Kinases	2022
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer, 2022, 10-01, Volume: 128, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ipilimumab; Male; Middle Aged; Nivolumab	2022
[GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience]. Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:2 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Neutropenia; Thrombocytopenia; Treatment Outcome	2023
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nature communications, 2023, 03-11, Volume: 14, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2023
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04). Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 07-05, Volume: 29, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neutropenia	2023
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). BMC cancer, 2023, May-22, Volume: 23, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine	2023
Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial). BMC cancer, 2023, Aug-07, Volume: 23, Issue:1 Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Clinical Trials, Phase II as Topic; Deoxycytidine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Young Adult	2023
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 12-01, Volume: 30, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Nausea; Oxonic Acid; Tegafur; Vomiting	2019
Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. British journal of cancer, 2020, Volume: 122, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Salvage Therapy	2020
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Phenylurea Compounds; Platinum; Pyridines; Treatment Outcome	2020
Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). The oncologist, 2021, Volume: 26, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bile Duct Neoplasms; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Treatment Outcome; Vascular Endothelial Growth Factor A	2021
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Cancer, 2021, 04-15, Volume: 127, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Progression-Free Survival; PTEN Phosphohydrolase; Pyrimidines; Quinazolines	2021
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. Cancer medicine, 2021, Volume: 10, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Hydroxamic Acids; Japan; Male; Middle Aged; Oxonic Acid; Placebos; Platinum Compounds; Progression-Free Survival; Sulfonamides; Tegafur; Young Adult	2021
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. Scientific reports, 2021, 06-18, Volume: 11, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers; Deoxycytidine; Disease Management; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Diseases; Kidney Function Tests; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Treatment Outcome	2021
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. European journal of cancer (Oxford, England : 1990), 2021, Volume: 154 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds	2021
Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases. Anticancer research, 2017, Volume: 37, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Biliary Tract Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2017
Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study. Oncology, 2018, Volume: 94, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies	2018
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. British journal of cancer, 2018, 02-20, Volume: 118, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Treatment Outcome	2018
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. PloS one, 2018, Volume: 13, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gallbladder Neoplasms; Gemcitabine; Gene Amplification; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis	2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British journal of cancer, 2018, Volume: 119, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Keratin-18; Male; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Quinazolines; Treatment Outcome; United Kingdom; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2018
Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. Journal of gastroenterology, 2019, Volume: 54, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Prognosis; Survival Rate; Treatment Outcome	2019
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of surgery, 2019, Volume: 270, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Postoperative Care; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome	2019
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-01, Volume: 25, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf	2019
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC cancer, 2019, Jan-11, Volume: 19, Issue:1 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Signal Transduction; Translational Research, Biomedical; Treatment Outcome	2019
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 05-01, Volume: 30, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Progression-Free Survival; Survival Rate	2019
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5 Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome	2013
A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome	2013
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer science, 2013, Volume: 104, Issue:9 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Tegafur	2013
A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer. International journal of clinical oncology, 2014, Volume: 19, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome	2014
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome	2013
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18 Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; DNA Mutational Analysis; Drug Administration Schedule; Exanthema; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Regression Analysis; Treatment Outcome	2013
A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged	2014
Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged	2014
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Quality of Life; Sirolimus; Survival Analysis	2014
Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden	2014
Is there a role for second-line platinum re-challenge in advanced biliary tract cancers? Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome	2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. British journal of cancer, 2014, Jul-29, Volume: 111, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome	2014
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatectomy; Humans; Male; Neutropenia; Postoperative Care; Pyridines; Tegafur; Treatment Outcome	2014
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Treatment Outcome	2014
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1 Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prodrugs; Survival Analysis; Tegafur	2015
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemokine CXCL12; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors	2014
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome	2015
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer. Investigational new drugs, 2015, Volume: 33, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cancer Vaccines; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Peptide Fragments; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2015
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Quinazolines	2015
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer. World journal of gastroenterology, 2014, Dec-28, Volume: 20, Issue:48 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome	2014
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur	2015
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cetuximab; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Phenotype; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Taiwan; Time Factors; Treatment Outcome	2015
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Failure	2015
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Tegafur	2015
Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism. AJR. American journal of roentgenology, 2015, Volume: 204, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Contrast Media; Deoxycytidine; Disease Progression; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2015
A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB : the official journal of the International Hepato Pancreato Biliary Association, 2015, Volume: 17, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome	2015
Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer. Journal of hepato-biliary-pancreatic sciences, 2015, Volume: 22, Issue:9 Topics: Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome	2015
Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer. World journal of gastroenterology, 2015, May-21, Volume: 21, Issue:19 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome	2015
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Neutrophils	2015
Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer, 2015, Sep-15, Volume: 121, Issue:18 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Salvage Therapy; Treatment Outcome	2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; United Kingdom	2015
Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC cancer, 2015, Jul-21, Volume: 15 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Tumor Burden	2015
Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. Journal of hepato-biliary-pancreatic sciences, 2015, Volume: 22, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome	2015
Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma. Acta oncologica (Stockholm, Sweden), 2016, Volume: 55, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Young Adult	2016
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. American journal of clinical oncology, 2018, Volume: 41, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome	2018
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer, 2016, Feb-15, Volume: 122, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Treatment Outcome	2016
Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:6 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Constipation; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Thrombocytopenia; Treatment Outcome	2015
Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Cancer science, 2016, Volume: 107, Issue:2 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms	2016
Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. Japanese journal of clinical oncology, 2016, Volume: 46, Issue:2 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome	2016
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Investigational new drugs, 2016, Volume: 34, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome	2016
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC cancer, 2016, Feb-24, Volume: 16 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cause of Death; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome	2016
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Japanese journal of clinical oncology, 2016, Volume: 46, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Oxonic Acid; Patient Selection; Tegafur; Treatment Outcome	2016
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Scientific reports, 2016, 05-03, Volume: 6 Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cetuximab; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Treatment Outcome	2016
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Australia; Biliary Tract Neoplasms; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Panitumumab; Patient Selection; Prospective Studies; Proto-Oncogene Proteins p21(ras); Survival Rate; Treatment Outcome	2016
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer. American journal of clinical oncology, 2018, Volume: 41, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quality of Life; Survival Rate	2018
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. Anticancer research, 2017, Volume: 37, Issue:2 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome; Vomiting	2017
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2008
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22 Topics: Administration, Oral; Adult; Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Staging; Pain; Pain Measurement; Palliative Care; Quality of Life; Switzerland; Time Factors; Treatment Outcome	2008
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Journal of gastrointestinal cancer, 2007, Volume: 38, Issue:2-4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome	2007
A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome	2009
Gemcitabine, irinotecan and celecoxib in patients with biliary cancer. Anti-cancer drugs, 2009, Volume: 20, Issue:4 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Celecoxib; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Thrombocytopenia; Treatment Outcome	2009
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. British journal of cancer, 2008, Sep-16, Volume: 99, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Humans; International Agencies; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Survival Rate; Time Factors; Treatment Outcome	2008
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology, 2009, Volume: 76, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Carcinoma, Pancreatic Ductal; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Pyrazoles; Sulfonamides	2009
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. American journal of clinical oncology, 2009, Volume: 32, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chi-Square Distribution; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Remission Induction; Risk Assessment; Survival Analysis	2009
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study. Pancreas, 2009, Volume: 38, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms	2009
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Thrombocytopenia; Treatment Outcome	2010
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. British journal of cancer, 2009, Aug-18, Volume: 101, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged	2009
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome	2010
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. The Lancet. Oncology, 2010, Volume: 11, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Risk Assessment; Time Factors; Treatment Outcome	2010
Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer. The oncologist, 2010, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome	2010
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Investigational new drugs, 2011, Volume: 29, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Survival Analysis; Time Factors; Treatment Outcome	2011
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine, 2010, Apr-08, Volume: 362, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Patient Compliance; Proportional Hazards Models	2010
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010, Volume: 95, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Compliance; Treatment Outcome	2010
Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Survival; Treatment Outcome	2011
Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Investigational new drugs, 2011, Volume: 29, Issue:6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Survival Rate; Treatment Outcome	2011
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. British journal of cancer, 2010, Aug-10, Volume: 103, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Treatment Outcome	2010
Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). Japanese journal of clinical oncology, 2010, Volume: 40, Issue:12 Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Japan; Male; Middle Aged; Oxonic Acid; Patient Selection; Sample Size; Survival Analysis; Tegafur; Treatment Outcome	2010
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010, Volume: 12, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Missouri; Survival Rate; Time Factors; Treatment Outcome	2010
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur	2011
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Failure	2012
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Fine-Needle; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatic Insufficiency; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Pyridines; Ribonucleotide Reductases; RNA, Messenger; Survival Analysis; Thiosemicarbazones	2011
A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis	2011
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. The Lancet. Oncology, 2010, Volume: 11, Issue:12 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins	2010
Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. Journal of immunotherapy (Hagerstown, Md. : 1997), 2011, Volume: 34, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; RNA Splicing Factors; Vaccines, Subunit	2011
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. American journal of clinical oncology, 2012, Volume: 35, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome	2012
Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer. Chemotherapy, 2011, Volume: 57, Issue:3 Topics: Adult; Aged; Alanine Transaminase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Positron-Emission Tomography; Survival Rate; Thrombocytopenia; Tomography, X-Ray Computed	2011
Brief commentary: largest randomized trial of biliary tract cancer treatment with cisplatin plus gemcitabine versus gemcitabine alone: an excellent opportunity to evaluate the prognostic value of tumor marker CA 19-9. Clinical colorectal cancer, 2011, Mar-01, Volume: 10, Issue:1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Prognosis	2011
A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer. International journal of clinical oncology, 2012, Volume: 17, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Male; Middle Aged; Treatment Outcome	2012
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology, 2012, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines	2012
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur	2012
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur	2012
Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplat Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Cisplatin; Combined Modality Therapy; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Nuclear Proteins; Pancreatic Neoplasms; Research Design; RNA Splicing Factors; Treatment Outcome; Vaccines, Subunit	2012
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. Oncology, 2012, Volume: 82, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging	2012
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Statistics, Nonparametric; Treatment Outcome	2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Thrombocytopenia; Treatment Outcome	2012
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer. American journal of clinical oncology, 2013, Volume: 36, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult	2013
Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2012, Volume: 79, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Treatment Outcome	2012
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Investigational new drugs, 2013, Volume: 31, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome; Wisconsin	2013
A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Patient Compliance; Tegafur	2013
Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Investigational new drugs, 2002, Volume: 20, Issue:3 Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Survival Analysis; Taxoids	2002
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients. Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms	2002
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. American journal of clinical oncology, 2003, Volume: 26, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis	2003
Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Pancreatic Neoplasms; Research Design	2003
Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome	2003
Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Investigational new drugs, 2004, Volume: 22, Issue:2 Topics: Aged; Biliary Tract Neoplasms; Cholangiocarcinoma; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Middle Aged; Survival Rate	2004
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Treatment Outcome	2004
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. British journal of cancer, 2004, May-04, Volume: 90, Issue:9 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Treatment Outcome	2004
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting	2004
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer, 2005, Jan-01, Volume: 103, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Survival Analysis	2005
Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Treatment Outcome	2005
Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Japanese journal of clinical oncology, 2005, Volume: 35, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia	2005
Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC cancer, 2005, Jun-12, Volume: 5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Models, Statistical; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2005
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer, 2005, Sep-15, Volume: 104, Issue:6 Topics: Adenocarcinoma; Biliary Tract Neoplasms; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Survival Rate	2005
Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Ribonucleotide Reductases; Survival Rate	2006
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer, 2005, Dec-15, Volume: 104, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle; Bone Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome	2005
Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer, 2006, Jan-15, Volume: 106, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome	2006
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 2006, Mar-15, Volume: 106, Issue:6 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Treatment Outcome	2006
Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome	2006
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome	2006
Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. British journal of cancer, 2006, Oct-09, Volume: 95, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Home Infusion Therapy; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome	2006
Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Recurrence; Survival Analysis	2007
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting	2008
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer, 2007, Sep-15, Volume: 110, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome	2007
Intra-arterial and systemic chemotherapy plus external hyperthermia in unresectable biliary cancer. Clinical oncology (Royal College of Radiologists (Great Britain)), 2007, Volume: 19, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Middle Aged; Pilot Projects	2007
A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer, 2007, Dec-15, Volume: 110, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate	2007
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. British journal of cancer, 2008, Jan-29, Volume: 98, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome	2008
Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology, 2007, Volume: 73, Issue:5-6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Tomography, X-Ray Computed	2007
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology, 1999, Volume: 56, Issue:3 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Survival Analysis; Treatment Outcome	1999
Biliary tract cancer: our experience with gemcitabine treatment. Anti-cancer drugs, 2000, Volume: 11, Issue:9 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged	2000
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome	2001
Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study. Cancer investigation, 2002, Volume: 20, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostatic Neoplasms	2002

Other Studies

150 other study(ies) available for deoxycytidine and Biliary Tract Neoplasms

Article	Year
Efficacy and Feasibility of Adjuvant Gemcitabine Plus Cisplatin Chemotherapy After Major Hepatectomy for Biliary Tract Cancer. Anticancer research, 2021, Volume: 41, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate	2021
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. Expert review of gastroenterology & hepatology, 2022, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Bridged-Ring Compounds; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Practice Patterns, Physicians'; Pyrimidines; Registries; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome	2022
A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain. Anticancer research, 2022, Volume: 42, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Blood Vessels; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Male; Middle Aged; Pain; Pancreatic Neoplasms	2022
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer. The Lancet. Oncology, 2022, Volume: 23, Issue:1 Topics: Biliary Tract Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin	2022
ASO Author Reflections: ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer. Annals of surgical oncology, 2022, Volume: 29, Issue:5 Topics: Biliary Tract Neoplasms; Cholesterol Esters; Deoxycytidine; Gemcitabine; Humans	2022
ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer. Annals of surgical oncology, 2022, Volume: 29, Issue:5 Topics: Acyltransferases; Biliary Tract Neoplasms; Cholesterol Esters; Deoxycytidine; Gemcitabine; Humans; RNA, Small Interfering	2022
Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis. Gut and liver, 2022, 09-15, Volume: 16, Issue:5 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Propensity Score	2022
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. Scientific reports, 2022, 01-19, Volume: 12, Issue:1 Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome	2022
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. Journal of chemotherapy (Florence, Italy), 2022, Volume: 34, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Hospitals; Humans; Male	2022
First-line chemotherapy plus immunotherapy in biliary tract cancer. The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:6 Topics: Biliary Tract Neoplasms; Deoxycytidine; Humans; Immunotherapy	2022
Evaluation of risk factors for chemotherapy-induced nausea and vomiting in cisplatin and gemcitabine treatment for biliary tract cancer: acid suppressants do not prevent nausea. Die Pharmazie, 2022, 06-01, Volume: 77, Issue:6 Topics: Anorexia; Antiemetics; Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Nausea; Risk Factors; Vomiting	2022
Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy. Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biliary Tract Neoplasms; Deoxycytidine; Humans; Immune Checkpoint Inhibitors; Middle Aged; Oxaliplatin; Prospective Studies	2023
[Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2022, Volume: 142, Issue:9 Topics: Biliary Tract Neoplasms; Deoxycytidine; Gemcitabine; Humans; Oxonic Acid; Prognosis; Pyridines; Recurrence; Retrospective Studies; Tegafur	2022
Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study. Oncology reports, 2023, Volume: 49, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Retrospective Studies; Treatment Outcome	2023
Epithelial-Mesenchymal Transition Phenotype and Peritumoral Immune Cell Infiltration in Advanced Biliary Tract Cancer. Anticancer research, 2023, Volume: 43, Issue:2 Topics: Bile Duct Neoplasms; Biliary Tract Neoplasms; Biomarkers, Tumor; Cadherins; Deoxycytidine; Epithelial-Mesenchymal Transition; Humans; Phenotype; Vimentin	2023
Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Frontiers in immunology, 2023, Volume: 14 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Deoxycytidine; Humans; Immune Checkpoint Inhibitors; Oxaliplatin; Retrospective Studies	2023
Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer. International journal of clinical pharmacy, 2023, Volume: 45, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans	2023
An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study. BMC gastroenterology, 2023, Aug-01, Volume: 23, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Cohort Studies; Deoxycytidine; East Asian People; Gemcitabine; Humans	2023
Development of a nomogram to predict survival in advanced biliary tract cancer. Scientific reports, 2023, Dec-06, Volume: 13, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Nomograms; Prognosis	2023
Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines. Cells, 2019, 09-03, Volume: 8, Issue:9 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitory Concentration 50	2019
[Ⅰ.Adverse Effects of Gemcitabine/CDDP Therapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Followed by Conversion Surgery]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Gemcitabine; Humans	2019
Systemic treatment of biliary tract cancer: now we have the evidence. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 12-01, Volume: 30, Issue:12 Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2019
Clinicopathological features and prognosis of surgical resected cases of biliary cancer with pancreaticobiliary maljunction. Hepatobiliary & pancreatic diseases international : HBPD INT, 2020, Volume: 19, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholecystectomy; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Pancreaticobiliary Maljunction; Pancreaticoduodenectomy; Prognosis	2020
Heterogeneity of Treg/Th17 According to Cancer Progression and Modification in Biliary Tract Cancers via Self-Producing Cytokines. Digestive diseases and sciences, 2020, Volume: 65, Issue:10 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Differentiation; Cells, Cultured; Coculture Techniques; Cytokines; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Forkhead Transcription Factors; Gemcitabine; Humans; Interleukin-17; Interleukin-6; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Phenotype; Retrospective Studies; T-Lymphocytes, Regulatory; Th17 Cells; Transforming Growth Factor beta1; Tumor Microenvironment	2020
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology (Baltimore, Md.), 2020, Volume: 72, Issue:3 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Cisplatin; CRISPR-Cas Systems; Deoxycytidine; Drug Discovery; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; High-Throughput Screening Assays; Humans; MicroRNAs; Xenograft Model Antitumor Assays	2020
Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis. PloS one, 2020, Volume: 15, Issue:1 Topics: Biliary Tract Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Caspase Inhibitors; Cell Cycle Checkpoints; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Necroptosis; Protein Kinases; Receptor-Interacting Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Triazoles; Tumor Necrosis Factor-alpha	2020
The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen. Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Carcinoma; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Nutrition Assessment; Organoplatinum Compounds; Prognosis; Progression-Free Survival; Risk Assessment	2021
[Biliary tract cancer: on the way to a personalized therapy]. Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Leucovorin; Organoplatinum Compounds; Palliative Care; Precision Medicine	2020
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study. Oncology reports, 2020, Volume: 43, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome	2020
Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience. BMC cancer, 2020, May-14, Volume: 20, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Taiwan	2020
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biliary Tract Neoplasms; Cell Proliferation; Cisplatin; Cytidine Monophosphate; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020
Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers. Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Prognosis; Progression-Free Survival; Retrospective Studies	2021
Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:10 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Gemcitabine; Humans; Oxaliplatin; Survival Analysis	2020
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Retrospective Studies; Treatment Outcome	2020
Reaching out beyond first-line treatments in advanced biliary tract cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Phenylurea Compounds; Platinum; Pyridines	2020
[Evaluation of the Tolerability of Gemcitabine and Cisplatin Combination Chemotherapy with a Small Quantity of Replacement Fluid for Biliary Tract Cancer]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2020, Volume: 140, Issue:7 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluid Therapy; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies	2020
Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 11-01, Volume: 26, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Animals; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cell Proliferation; Chitinase-3-Like Protein 1; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Interleukin-6; Male; Mice; Middle Aged; Palliative Care; Prognosis; Progression-Free Survival; Receptors, Interleukin-6	2020
ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner. Biomolecules, 2020, 11-09, Volume: 10, Issue:11 Topics: Ataxia Telangiectasia Mutated Proteins; Biliary Tract Neoplasms; Cell Line, Tumor; Deoxycytidine; DNA Polymerase theta; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Protein Kinase Inhibitors	2020
Chemotherapy for biliary tract cancer: real-world experience in a single institute. Nagoya journal of medical science, 2020, Volume: 82, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies	2020
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. Investigational new drugs, 2021, Volume: 39, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur	2021
Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology (Baltimore, Md.), 2022, Volume: 75, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biliary Tract Neoplasms; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays	2022
Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression on Prognosis After Surgical Resection for Biliary Carcinoma. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2017, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Osteonectin; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis	2017
Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. Investigational new drugs, 2018, Volume: 36, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Deoxycytidine; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Progression-Free Survival	2018
Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta oncologica (Stockholm, Sweden), 2018, Volume: 57, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Treatment Outcome	2018
Effect of midkine on gemcitabine resistance in biliary tract cancer. International journal of molecular medicine, 2018, Volume: 41, Issue:4 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Midkine	2018
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. Japanese journal of clinical oncology, 2018, Apr-01, Volume: 48, Issue:4 Topics: Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Inhibitory Concentration 50; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyridines; Quinolones; Signal Transduction; TOR Serine-Threonine Kinases	2018
The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer. Anticancer research, 2018, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Tegafur; Treatment Outcome	2018
Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients. BMC cancer, 2018, 03-21, Volume: 18, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mast Cells; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Proportional Hazards Models; T-Lymphocyte Subsets; Tissue Array Analysis	2018
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer. Annals of surgical oncology, 2018, Volume: 25, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Male; Neoplasm Recurrence, Local; Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase; Prognosis; Survival Rate	2018
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. Cancer research and treatment, 2019, Volume: 51, Issue:3 Topics: Aged; Biliary Tract Neoplasms; Case-Control Studies; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Survival Analysis; Treatment Outcome; Watchful Waiting	2019
Adjuvant Therapy for Biliary Tract Cancers: New Evidence to Resolve Old Questions. Journal of oncology practice, 2018, Volume: 14, Issue:12 Topics: Biliary Tract Neoplasms; Deoxycytidine; Humans	2018
Adjuvant Therapy for Biliary Tract Cancers: Desperately Seeking Data. Journal of oncology practice, 2018, Volume: 14, Issue:12 Topics: Biliary Tract Neoplasms; Combined Modality Therapy; Deoxycytidine; Humans	2018
Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. PloS one, 2018, Volume: 13, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Neoplasms; Biomarkers; Cell Line, Tumor; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Middle Aged; Prognosis; RNA, Small Interfering	2018
KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study. Hepatobiliary & pancreatic diseases international : HBPD INT, 2019, Volume: 18, Issue:1 Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Salvage Therapy; Sodium Compounds; Time Factors; Tomography, X-Ray Computed	2019
[Treatment Outcomes of Gemcitabine and Cisplatin Combination Therapy for Unresectable and Recurrent Biliary Tract Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome	2018
Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors. Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome	2019
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis. Scientific reports, 2019, 04-03, Volume: 9, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Propensity Score; Time Factors; Treatment Outcome	2019
Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer: Closing the GAP. JAMA oncology, 2019, 06-01, Volume: 5, Issue:6 Topics: Albumins; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel	2019
Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC? The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:8 Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Japan; Neoplasm Recurrence, Local; Nivolumab	2019
Current therapy and future directions in biliary tract malignancies. Current treatment options in oncology, 2013, Volume: 14, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Retrospective Studies	2013
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. World journal of surgical oncology, 2013, May-27, Volume: 11 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins	2013
Comparative outcomes of elderly and non-elderly patients receiving first-line palliative chemotherapy for advanced biliary tract cancer. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Retrospective Studies; Tegafur; Treatment Outcome; Uracil	2014
A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer. Chemotherapy, 2013, Volume: 59, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Severity of Illness Index; Survival Rate	2013
Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology, 2013, Volume: 85, Issue:4 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking	2013
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC cancer, 2013, Oct-16, Volume: 13 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Fusion Regulatory Protein-1; Gemcitabine; Humans; Kaplan-Meier Estimate; Large Neutral Amino Acid-Transporter 1; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Retrospective Studies; Treatment Outcome; Xenograft Model Antitumor Assays	2013
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hyperbilirubinemia; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms	2014
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate	2013
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies	2014
ERCC1 in advanced biliary tract cancer patients treated with chemotherapy: prognostic and predictive roles. Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate	2014
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. Chemotherapy, 2013, Volume: 59, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasm Staging; Retrospective Studies; Treatment Outcome	2013
Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients. Fukuoka igaku zasshi = Hukuoka acta medica, 2013, Volume: 104, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome	2013
Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer. Oncology, 2014, Volume: 87, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Renal Insufficiency; Retrospective Studies	2014
Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Platinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome	2014
Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Chemotherapy, 2014, Volume: 60, Issue:1 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Databases, Factual; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Staging; Survival Rate; Treatment Outcome	2014
Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO). Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult	2014
Initial safety and efficacy of cisplatin and gemcitabine combination chemotherapy for unresectable biliary tract cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies	2014
BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer science, 2015, Volume: 106, Issue:5 Topics: AC133 Antigen; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; BRCA2 Protein; CD24 Antigen; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group D2 Protein; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hyaluronan Receptors; Male; Metabolic Networks and Pathways; Middle Aged; Peptides; Rad51 Recombinase; RNA, Small Interfering	2015
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. Anti-cancer drugs, 2015, Volume: 26, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis	2015
[Supportive management of cisplatin and gemcitabine combination therapy for advanced biliary tract cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging	2015
[hENT1, dCK, RRM, WFA-MY.1E12]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 3 Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Early Detection of Cancer; Gemcitabine; Humans; Prognosis	2015
[Current status and future directions in chemotherapy for biliary tract carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy	2015
Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer. Biomaterials, 2015, Volume: 53 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Hyaluronan Receptors; Nanoparticles; Paclitaxel	2015
Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bilirubin; Biomarkers; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Jaundice; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Patient Selection; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stents; Time Factors; Treatment Outcome; United Kingdom; Young Adult	2015
Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report. Anticancer research, 2015, Volume: 35, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur	2015
Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery. Annals of surgical oncology, 2015, Volume: 22 Suppl 3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Case-Control Studies; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Complications; Prognosis; Survival Rate	2015
Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer. Oncology, 2015, Volume: 89, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins	2015
[Gemcitabine in Combination with Cisplatin in Patients with Unresectable Advanced or Recurrent Biliary Tract Cancer--A Multicenter Prospective Observational Study in Fukuoka]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Recurrence; Treatment Outcome	2015
Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). PloS one, 2015, Volume: 10, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Treatment Outcome	2015
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. Journal of experimental & clinical cancer research : CR, 2015, Dec-23, Volume: 34 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome	2015
Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. Journal of clinical pathology, 2016, Volume: 69, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Rate; X-ray Repair Cross Complementing Protein 1	2016
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Scientific reports, 2016, Apr-11, Volume: 6 Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Retrospective Studies; ROC Curve; Severity of Illness Index; Treatment Outcome	2016
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer, 2016, 12-01, Volume: 122, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cyclin-Dependent Kinases; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Mutation; Organoplatinum Compounds; Prognosis; Surveys and Questionnaires; Treatment Outcome; Young Adult	2016
A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Pilot Projects; Tomography, X-Ray Computed; Treatment Outcome	2016
Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Asia-Pacific journal of clinical oncology, 2017, Volume: 13, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Treatment Outcome	2017
A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan. Journal of gastrointestinal cancer, 2017, Volume: 48, Issue:4 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male	2017
A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:4 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Klatskin Tumor; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreaticoduodenectomy; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed	2017
Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study. Investigational new drugs, 2017, Volume: 35, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Young Adult	2017
Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncology reports, 2008, Volume: 20, Issue:2 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins	2008
Postoperative adjuvant treatments for biliary tract cancer. Journal of hepato-biliary-pancreatic surgery, 2008, Volume: 15, Issue:5 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic	2008
[Two cases of advanced biliary tract cancer successfully treated with gemcitabine combination chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Tomography, X-Ray Computed	2008
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC cancer, 2008, Dec-18, Volume: 8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Palliative Care; Pyrimidinones; Retrospective Studies; Tegafur; Treatment Outcome; Uracil	2008
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. Clinical pharmacokinetics, 2009, Volume: 48, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biliary Tract Neoplasms; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Tandem Mass Spectrometry	2009
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine. Anticancer research, 2009, Volume: 29, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein	2009
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking	2009
[Seven cases of gemcitabine-induced lung injury during treatment for pancreatic or biliary tract cancers]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5 Topics: Aged; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Injury; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Tomography, X-Ray Computed	2009
Features of gemcitabine-related severe pulmonary toxicity: patients with pancreatic or biliary tract cancer. Pancreas, 2009, Volume: 38, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Lung Diseases; Male; Middle Aged; Pancreatic Neoplasms; Pneumonia	2009
Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Annals of surgery, 2009, Volume: 250, Issue:6 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Hepatectomy; Humans; Immunosuppressive Agents; Japan; Male; Oxonic Acid; Pancreaticoduodenectomy; Postoperative Care; Survival Rate; Tegafur; Time Factors; Treatment Outcome	2009
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World journal of gastroenterology, 2010, Jan-14, Volume: 16, Issue:2 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Proto-Oncogene Proteins c-akt; Pteridines; Pyrimidines; Pyrroles; Receptor, IGF Type 1	2010
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer science, 2010, Volume: 101, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, SCID; Microtubule-Associated Proteins; Neoplasm Proteins; Specific Pathogen-Free Organisms	2010
Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert opinion on drug safety, 2010, Volume: 9, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Organoplatinum Compounds; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome	2010
Targeted therapy for biliary-tract cancer. The Lancet. Oncology, 2010, Volume: 11, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Risk Assessment; Time Factors; Treatment Outcome	2010
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer, 2010, May-01, Volume: 116, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged	2010
A step forward in the treatment of advanced biliary tract cancer. The New England journal of medicine, 2010, Apr-08, Volume: 362, Issue:14 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Research Design	2010
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Severity of Illness Index; Treatment Outcome	2010
Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma. Chemotherapy, 2010, Volume: 56, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome	2010
Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Palliative Care; Prognosis; Survival Rate; Tegafur; Tumor Burden; Young Adult	2011
Cisplatin plus gemcitabine for biliary tract cancer. The New England journal of medicine, 2010, Jul-08, Volume: 363, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Neoplasms, Squamous Cell; Pemetrexed	2010
Cisplatin plus gemcitabine for biliary tract cancer. The New England journal of medicine, 2010, Jul-08, Volume: 363, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans	2010
Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. International journal of oncology, 2010, Volume: 37, Issue:4 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Inhibitory Concentration 50; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Treatment Outcome; Tumor Suppressor Proteins	2010
Chemotherapy: Gemcitabine alone or plus cisplatin for biliary tract cancer? Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Survival Rate	2010
Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Comorbidity; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome	2011
Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; C-Reactive Protein; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Retrospective Studies; Serum Albumin; Treatment Outcome	2010
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC cancer, 2010, Nov-18, Volume: 10 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gallbladder Neoplasms; Gemcitabine; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction	2010
Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer. Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic	2012
Treatment of borderline cases for curative resection of biliary tract cancer. Journal of surgical oncology, 2011, Volume: 104, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Brachytherapy; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Treatment Outcome	2011
Biliary-tract cancer: improving therapy by adding molecularly targeted agents. The Lancet. Oncology, 2012, Volume: 13, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Quinazolines	2012
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Investigational new drugs, 2012, Volume: 30, Issue:6 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; MAP Kinase Signaling System; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolinones; Receptors, Growth Factor; STAT3 Transcription Factor	2012
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors. Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Proportional Hazards Models; Tegafur	2012
Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study. HPB : the official journal of the International Hepato Pancreato Biliary Association, 2012, Volume: 14, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangitis; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Drainage; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoadjuvant Therapy; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2012
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. Hepato-gastroenterology, 2012, Volume: 59, Issue:115 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2012
[The evaluation of chemotherapy for patients over eighty-years-old]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:4 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms	2012
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anti-cancer drugs, 2012, Volume: 23, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangitis; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Peripheral Nervous System Diseases; Retrospective Studies; Sarcopenia; Severity of Illness Index; Thrombocytopenia; Treatment Outcome	2012
A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome	2012
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. Chemotherapy, 2012, Volume: 58, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; CA-19-9 Antigen; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies	2012
Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Asian People; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Exanthema; Female; Fever; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Liver Function Tests; Male; Middle Aged; Product Surveillance, Postmarketing; Treatment Outcome; Young Adult	2012
Photodynamic therapy for pancreatic and biliary tract cancer: the United Kingdom experience. Journal of the National Comprehensive Cancer Network : JNCCN, 2012, Oct-01, Volume: 10 Suppl 2 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Photochemotherapy; Survival Rate; Treatment Outcome; United Kingdom	2012
Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jan-01, Volume: 19, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Tumor Burden; Xenograft Model Antitumor Assays	2013
Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany. Onkologie, 2012, Volume: 35, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Endoscopy; Female; Fluorouracil; Gemcitabine; Germany; Health Care Surveys; Humans; Male; Medical Oncology; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Patterns, Physicians'; Treatment Outcome; Young Adult	2012
Synergistic effect between Juzen-taiho-to, a Japanese traditional herbal medicine, and gemcitabine single-agent chemotherapy for advanced biliary tract cancer. Journal of alternative and complementary medicine (New York, N.Y.), 2013, Volume: 19, Issue:6 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Medicine, Kampo	2013
Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:7 Topics: Aged; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-6; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Smad4 Protein; Transforming Growth Factor beta1	2013
Improvement of prognosis for unresectable biliary tract cancer. World journal of gastroenterology, 2013, Jan-07, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome	2013
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas. Anti-cancer drugs, 2003, Volume: 14, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Palliative Care	2003
[Experience of gemcitabine therapy after non-curative resection for biliary tract cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:9 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male	2005
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. British journal of cancer, 2007, Mar-26, Volume: 96, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin	2007
Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncology reports, 2007, Volume: 17, Issue:5 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins	2007
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World journal of gastroenterology, 2007, Sep-21, Volume: 13, Issue:35 Topics: Animals; Apoptosis; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Enzyme Inhibitors; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Mice, Nude; Panobinostat; Xenograft Model Antitumor Assays	2007
Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Drainage; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Predictive Value of Tests; Stents; Treatment Outcome	2007
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Oxonic Acid; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur	2007
[Irinotecan plus gemcitabine(IRINOGEM)in the treatment of biliary malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Tomography, X-Ray Computed	2008
Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer. International journal of pancreatology : official journal of the International Association of Pancreatology, 2000, Volume: 27, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms	2000